Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivanib alaninate - ZAI Lab

Drug Profile

Brivanib alaninate - ZAI Lab

Alternative Names: BMS-540215; BMS-582664; Brivanib; ZL-2301

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Gynecologic Oncology Group; Hunan Cancer Hospital; National Cancer Institute (USA); ZAI Lab
  • Class Antineoplastics; Esters; Indoles; Pyrroles; Small molecules; Triazines
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I Ovarian cancer
  • No development reported Solid tumours
  • Discontinued Cervical cancer; Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 14 Jan 2019 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater, Combination therapy) in China (PO) (NCT03895788)
  • 26 Sep 2018 Additional efficacy data from a phase II trial in Hepatocellular carcinoma released by Zai Lab
  • 26 Sep 2018 Zai Lab plans a trial for Hepatocellular carcinoma (Combination therapy) in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top